Latest trial win further supports expanded use of Bristol Myers’ Opdivo in lung cancer

Bristol Myers Squibb’s Opdivo achieved positive results in a Phase 3 clinical trial studying the drug in people with early-stage non-small cell lung cancer before and after surgery, a finding that could further support its use in less severely ill patients.